PL3133070T3 - Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta - Google Patents

Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta

Info

Publication number
PL3133070T3
PL3133070T3 PL16175117T PL16175117T PL3133070T3 PL 3133070 T3 PL3133070 T3 PL 3133070T3 PL 16175117 T PL16175117 T PL 16175117T PL 16175117 T PL16175117 T PL 16175117T PL 3133070 T3 PL3133070 T3 PL 3133070T3
Authority
PL
Poland
Prior art keywords
disease
eliglustat
genz
tailoring
metabolism
Prior art date
Application number
PL16175117T
Other languages
English (en)
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P. Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3133070(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3133070T3 publication Critical patent/PL3133070T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
PL16175117T 2009-11-27 2010-11-24 Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta PL3133070T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27
EP16175117.7A EP3133070B1 (en) 2009-11-27 2010-11-24 Eliglustat (genz 112638) as inhibitor of glucosylceramide synthase for use in a method of treating fabry's or gaucher's disease, the method comprising adjusting the individual therapeutical dose to the p-450 metabolism of the patient
EP10785289.9A EP2504332B2 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
EP14164650.5A EP2796457B1 (en) 2009-11-27 2010-11-24 Genz 112638 for treating Gaucher or Fabry disease in combination therapy
EP16159714.1 2010-11-24
PCT/US2010/057952 WO2011066352A1 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase

Publications (1)

Publication Number Publication Date
PL3133070T3 true PL3133070T3 (pl) 2020-01-31

Family

ID=43431870

Family Applications (4)

Application Number Title Priority Date Filing Date
PL10785289T PL2504332T5 (pl) 2009-11-27 2010-11-24 Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej
PL16175117T PL3133070T3 (pl) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
PL19182732T PL3599237T3 (pl) 2009-11-27 2010-11-24 Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
PL14164650T PL2796457T3 (pl) 2009-11-27 2010-11-24 Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10785289T PL2504332T5 (pl) 2009-11-27 2010-11-24 Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL19182732T PL3599237T3 (pl) 2009-11-27 2010-11-24 Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
PL14164650T PL2796457T3 (pl) 2009-11-27 2010-11-24 Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego

Country Status (40)

Country Link
US (7) US11458119B2 (pl)
EP (5) EP2796457B1 (pl)
JP (6) JP2013512252A (pl)
KR (6) KR20120115972A (pl)
CN (5) CN102712629B (pl)
AR (3) AR079152A1 (pl)
AU (3) AU2010324810B2 (pl)
BR (1) BR112012012947B8 (pl)
CA (3) CA3140959A1 (pl)
CL (2) CL2012001348A1 (pl)
CR (1) CR20120277A (pl)
CY (3) CY1115880T1 (pl)
DK (3) DK2796457T3 (pl)
DO (2) DOP2012000141A (pl)
EA (3) EA201890254A3 (pl)
EC (2) ECSP12011926A (pl)
ES (4) ES2586947T3 (pl)
GT (1) GT201200161A (pl)
HR (3) HRP20140780T4 (pl)
HU (2) HUE029371T2 (pl)
IL (4) IL310635A (pl)
LT (2) LT3133070T (pl)
MA (1) MA33838B1 (pl)
ME (1) ME02477B (pl)
MX (2) MX381242B (pl)
MY (2) MY160542A (pl)
NI (1) NI201200096A (pl)
NZ (3) NZ715108A (pl)
PE (2) PE20171255A1 (pl)
PH (2) PH12015502514B1 (pl)
PL (4) PL2504332T5 (pl)
PT (4) PT2504332E (pl)
RS (3) RS59543B1 (pl)
SG (2) SG10201407881WA (pl)
SI (3) SI3133070T1 (pl)
SM (1) SMT201600273B (pl)
TN (1) TN2012000237A1 (pl)
TW (3) TWI586663B (pl)
UA (1) UA113491C2 (pl)
WO (1) WO2011066352A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
CA3140959A1 (en) 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
US9155784B2 (en) * 2011-06-20 2015-10-13 Icahn School Of Medicine At Mount Sinai Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
LT2753346T (lt) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidazė ir ląstelių diferenciacija
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
JP6537500B2 (ja) * 2013-09-20 2019-07-03 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患治療用のグルコシルセラミドシンターゼ阻害剤
EP3164128A4 (en) * 2014-07-03 2018-02-28 Dr. Reddy's Laboratories Ltd. Amorphous form of eliglustat hemitartarate
EP3283483B1 (en) 2015-04-14 2018-12-19 Sandoz AG Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MX2018006250A (es) 2015-11-18 2018-09-05 Genzyme Corp Biomarcador de enfermedad poliquistica renal y usos del mismo.
SG11201807012QA (en) 2016-02-25 2018-09-27 Asceneuron S A Acid addition salts of piperazine derivatives
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) * 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
TW201904577A (zh) * 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
WO2019030645A1 (en) 2017-08-08 2019-02-14 Kashiv Pharma Llc Pharmaceutical composition comprising eliglustat
US12472144B2 (en) * 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
AU2018386182B2 (en) 2017-12-15 2024-03-28 Genzyme Corporation Methods for treating Gaucher disease
US12064414B2 (en) 2017-12-20 2024-08-20 Aizant Drug Research Solutions Private Limited. Stable amorphous Eliglustat premix and process for the preparation thereof
US11760741B2 (en) 2018-05-02 2023-09-19 Kashiv Biosciences, Llc Pro-drugs of eliglustat
AU2019276882A1 (en) * 2018-05-27 2021-01-14 Bioasis Technolgies Inc. Treatment of gaucher disease
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
AU2021455177B2 (en) * 2021-07-05 2025-01-09 Asceneuron Sa Medicaments comprising glycosidase inhibitors
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
WO2026006099A1 (en) 2024-06-24 2026-01-02 Genzyme Corporation Eliglustat for the treatment of gaucher disease
EP4725474A1 (en) 2024-10-11 2026-04-15 Genepharm S.A. A solid composition of eliglustat

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
JPH09508900A (ja) 1994-02-02 1997-09-09 ザ リポソーム カンパニー、インコーポレーテッド 薬理学的に活性な化合物及びリポソーム並びにそれらの使用方法
US5763438A (en) 1994-06-10 1998-06-09 Seikagaku Corporation 2-acylaminopropanol compound and medical composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
ATE358473T1 (de) 1998-07-27 2007-04-15 Univ Johns Hopkins Diamino-propanol-verbindungen zur behandlung von ischaemien
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
BR0012318A (pt) * 1999-07-09 2002-05-28 Univ Michigan Compostos semelhantes a amino ceramida e métodos terapêuticos de uso
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
ES2239558T3 (es) 2000-04-24 2007-04-01 Teva Pharmaceutical Industries Ltd. Hemitartrato de zolpidem micronizado.
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP2004531478A (ja) 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
JP2004525621A (ja) 2001-01-18 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング グルコセレブロシダーゼ活性を有する二機能性融合タンパク質
EP2067775B1 (en) * 2001-07-16 2012-04-25 Genzyme Corporation A N-Acylsphingosine glucosyltransferase inhibitor
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
EP2206702B1 (en) 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Bicyclic compound, production and use thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
AU2003251829B2 (en) 2002-07-09 2009-12-10 Radical Therapeutix Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
AR047459A1 (es) * 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
AU2005284727A1 (en) 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
WO2006039663A2 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals, Inc Methods for the administration of iloperidone
KR100872675B1 (ko) 2004-10-13 2008-12-10 파마시아 앤드 업존 캄파니 엘엘씨 3-[5-클로로-4-[(2,4-디플루오로벤질)옥시]-6-옥소피리미딘-1(6ｈ)-일]-ｎ-(2-히드록시에틸)-4-메틸벤즈아미드의결정형
EP1811991B1 (en) † 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
AU2006297475A1 (en) * 2005-10-03 2007-04-12 Mallinckrodt Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
SI2032134T1 (sl) * 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
CN101631536A (zh) * 2007-01-12 2010-01-20 惠氏公司 片中片组合物
MX2009010557A (es) * 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
EP2594564B1 (en) * 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090307180A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
PL2604608T3 (pl) 2009-11-27 2016-02-29 Adverio Pharma Gmbh Sposób wytwarzania {4,6-diamino-2-[1-(2-fluorobenzylo)-1H-pirazolo[3,4-b]pirydyn-3-ylo]pirymidyn-5-ylo}metylokarbaminianu metylu
CA3140959A1 (en) 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
US9006270B2 (en) 2011-06-21 2015-04-14 Novartis Ag Polymorphs of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
PT2504332E (pt) 2014-09-02
CY1122698T1 (el) 2021-03-12
HRP20140780T4 (hr) 2021-08-06
SG10201407881WA (en) 2015-01-29
SI2504332T1 (sl) 2014-09-30
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
EA029990B1 (ru) 2018-06-29
ES2493940T5 (es) 2021-11-23
PT2796457T (pt) 2016-07-14
IL260299A (en) 2018-08-30
TW201639562A (zh) 2016-11-16
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
BR112012012947A2 (pt) 2017-03-01
IL283935A (en) 2021-07-29
UA113491C2 (xx) 2017-02-10
US10888547B2 (en) 2021-01-12
CA2781676C (en) 2020-05-05
PT3133070T (pt) 2019-11-11
CA3140959A1 (en) 2011-06-03
US20130137743A1 (en) 2013-05-30
KR20180049255A (ko) 2018-05-10
TW201737910A (zh) 2017-11-01
DK2504332T3 (da) 2014-08-25
BR112012012947B8 (pt) 2021-05-25
CN105777707B (zh) 2020-10-13
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
AU2017265180B2 (en) 2019-08-01
NI201200096A (es) 2012-10-30
EA023923B1 (ru) 2016-07-29
JP2013512252A (ja) 2013-04-11
MY192644A (en) 2022-08-29
PH12015502514B1 (en) 2022-07-29
AR079152A1 (es) 2011-12-28
CN112521367A (zh) 2021-03-19
WO2011066352A1 (en) 2011-06-03
SMT201600273B (it) 2016-08-31
RS59543B1 (sr) 2019-12-31
DK2796457T3 (en) 2016-08-29
PL2504332T3 (pl) 2014-10-31
EP3133070B1 (en) 2019-08-14
CR20120277A (es) 2012-09-05
CL2016002589A1 (es) 2017-05-19
WO2011066352A8 (en) 2011-08-11
EP3133070A1 (en) 2017-02-22
ES2754398T3 (es) 2020-04-17
CA2781676A1 (en) 2011-06-03
ECSP12011926A (es) 2012-07-31
CY1117996T1 (el) 2017-05-17
US20160166542A1 (en) 2016-06-16
CN112521366A (zh) 2021-03-19
LT3133070T (lt) 2019-11-11
AU2010324810A1 (en) 2012-06-07
JP2020189873A (ja) 2020-11-26
IL310635A (en) 2024-04-01
MA33838B1 (fr) 2012-12-03
US20160120842A1 (en) 2016-05-05
EP2504332B1 (en) 2014-06-04
JP2015212291A (ja) 2015-11-26
IL219892A0 (en) 2012-07-31
EP3896069A1 (en) 2021-10-20
HK1203485A1 (en) 2015-10-30
HRP20140780T1 (en) 2014-11-07
GT201200161A (es) 2014-01-27
HRP20191647T1 (hr) 2019-12-13
EA201890254A3 (ru) 2019-02-28
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
TWI586663B (zh) 2017-06-11
DOP2012000141A (es) 2012-09-30
MY160542A (en) 2017-03-15
EP2796457B1 (en) 2016-05-18
RS53503B2 (sr) 2021-07-30
CY1115880T1 (el) 2017-01-25
CA3075788C (en) 2021-12-21
KR20250005503A (ko) 2025-01-09
CN102712629A (zh) 2012-10-03
RS53503B1 (sr) 2015-02-27
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
PE20171255A1 (es) 2017-08-28
CN102712629B (zh) 2016-10-12
ES2586947T3 (es) 2016-10-19
PH12015502514A1 (en) 2016-08-15
KR20200013105A (ko) 2020-02-05
SI2796457T1 (sl) 2016-10-28
EA201270646A1 (ru) 2013-01-30
EP2796457A1 (en) 2014-10-29
PH12012501048A1 (en) 2013-02-04
US20260115165A1 (en) 2026-04-30
NZ715108A (en) 2017-06-30
BR112012012947B1 (pt) 2021-04-06
JP7150528B2 (ja) 2022-10-11
AR121612A2 (es) 2022-06-22
DK3133070T3 (da) 2019-11-11
CA3075788A1 (en) 2011-06-03
EP3599237A1 (en) 2020-01-29
US12465586B2 (en) 2025-11-11
HUE045784T2 (hu) 2020-01-28
JP6370264B2 (ja) 2018-08-08
US20230172903A1 (en) 2023-06-08
MX2012006083A (es) 2012-06-19
CL2012001348A1 (es) 2012-08-24
AU2017265180A1 (en) 2017-12-14
AU2016202591B2 (en) 2017-11-30
HUE029371T2 (en) 2017-02-28
CN105753846B (zh) 2019-11-15
LT2796457T (lt) 2016-09-12
JP2019001809A (ja) 2019-01-10
ES2493940T3 (es) 2014-09-12
AU2016202591A1 (en) 2016-05-19
RS54978B1 (sr) 2016-11-30
SI2504332T2 (sl) 2021-08-31
ES2875382T3 (es) 2021-11-10
EP3599237B1 (en) 2021-03-24
MX381242B (es) 2025-03-12
EA201592195A1 (ru) 2016-04-29
TWI656873B (zh) 2019-04-21
PL2796457T3 (pl) 2017-04-28
JP2016138124A (ja) 2016-08-04
KR20220162824A (ko) 2022-12-08
PL2504332T5 (pl) 2021-08-23
NZ600155A (en) 2014-10-31
TN2012000237A1 (en) 2013-12-12
US20210369672A1 (en) 2021-12-02
CN112521367B (zh) 2024-01-02
SG10201800136QA (en) 2018-02-27
SI3133070T1 (sl) 2019-11-29
EA201890254A2 (ru) 2018-10-31
JP6452635B2 (ja) 2019-01-16
EP2504332B2 (en) 2021-03-17
KR20120115972A (ko) 2012-10-19
US11458119B2 (en) 2022-10-04
DOP2016000250A (es) 2017-02-15
JP2023116764A (ja) 2023-08-22
ECSP18063798A (es) 2020-02-28
PT3599237T (pt) 2021-04-28
TW201130822A (en) 2011-09-16
ME02477B (me) 2017-02-20
KR20150125734A (ko) 2015-11-09
PL3599237T3 (pl) 2021-09-27
DK2504332T4 (da) 2021-06-07
HK1172031A1 (en) 2013-04-12
HRP20161038T1 (hr) 2016-10-21
EP2504332A1 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
PL3133070T3 (pl) Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
IL209231A0 (en) Scoring catheter for treating diseased heart valves
EP2417570A4 (en) METHOD FOR GENERATING KEYWORD-TRIGGERED, GEOGRAPHICALLY TARGETED ADVERTISING GENERATIONS AND USER-RECOVERABLE LAYER ADVERTISING GENERATIONS
IL203734A (en) Annotations of 6 - Triazolopyridazinesulfonyl Benzothiazole and Benzimidazole, a Method for their Preparation and Use as Medicines and Preparations
GB0700560D0 (en) Device and method for the treatment of diseased tissue such as tumours
EP2445451A4 (en) PATIENT-ADAPTED AND IMPROVED ORTHOPEDIC IMPLANTS, DESIGNS AND RELATED INSTRUMENTS
PL2209395T3 (pl) Urządzenie do traktowania włosów parą
EP2382176A4 (en) USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PT2292231E (pt) Agente terapêutico para a estenose do canal espinal
AU324215S (en) Handpiece for massage or therapy
FI20085305A0 (fi) Menetelmä uutteen saamiseksi jossa on korkea määrä bioaktiivisia yhdisteitä, jäännös, jäännöksen käyttö ja uute
BR112013009970A2 (pt) método para determinar uma característica do ritmo circadiano de um paciente.
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
ITRE20060026A1 (it) Apparecchio per trattamenti medicinali
ITRE20060127A1 (it) Apparecchio per trattamenti medicali
IL260078B (en) Therapy used to treat Gaucher disease
IT1392227B1 (it) Macchina e metodo per il trattamento combinato meccanico e termico di tessuti
PT1847524E (pt) Derivados de terfenilo para o tratamento da doença de alzheimer
IL207247A0 (en) Use of ranolazine for the treatment of cardiovascular disease
IL225755A0 (en) Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain
PL2240486T3 (pl) Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
ITMO20070333A1 (it) Capsula, apparato e metodo